Search

JAKAVI 15 MG, Comprimé pelliculé

Details

--- Description
Pack Boite de 56
Strength (Dosage) 15 MG
Laboratory NOVARTIS PHARMA MAROC
Ingredients Ruxolitinib
Therapeutic class Immunosuppresseur sélectif, inhibiteur des Janus kinases
ATC code L01XE18
PPH $2,970.50
PPV $3,029.10
Refundable Yes
Refund base $3,029.10
Refund rate $0.00
Table A
Marketing status Commercialized
Type Not specified
Uses Myélofibrose (MF)
Jakavi est indiqué dans le traitement de la splénomégalie ou des symptômes liés à la maladie chez l’adulte atteint de myélofibrose primitive (appelée également myélofibrose chronique idiopathique), de myélofibrose secondaire à la maladie de Vaquez (polycythémie vraie) ou de myélofibrose secondaire à la thrombocytémie essentielle.
Warnings
Dosage
Avoid
Side effects
Interactions

Medications with one or more of the ingredients above


Medications under one or more of the therapeutic classes above


Medications from the same laboratory


Disclaimer
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.